<DOC>
	<DOC>NCT02195453</DOC>
	<brief_summary>The purpose of this study is to observe quality of life and treatment side effects in patients with advanced non small cell lung cancer (NSCLC) receive chemotherapy and Yangzhengxiaoji capsule.</brief_summary>
	<brief_title>Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criteria: 1. Histology and/or cytology confirmed stage Ⅳ NSCLC patients; 2. With at least one measurable solid tumor (RECIST standard version 1.1): tumor &gt;=10 mm in diameter on CT or MRI images, or lymph node &gt;=15 mm in diameter on CT or MRI images; 3. Eastern Cooperative Oncology Group(ECOG) score 01, expectant survival &gt; 3 months; 4. Age: 1870 years; 5. Normal organ function: Bone marrow: neutrophils (ANC) count&gt;=1.5×10^9/L, Platelets count&gt;=100×10^9/L, hemoglobin&gt;=90g/L；Renal function, serum creatinine&lt;=1.5 mg/dl, and/or creatinine clearance or&gt;=60 ml/min; Liver function: total serum bilirubin levels &lt;= 1.5 times the upper limit of normal (ULN), serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT)&lt;=2.5 times the ULN, if abnormal liver function caused by the underlying malignancy, the AST and ALT &gt;=5 times ULN; 6. For patients with brain metastases, bone metastases or pleural effusion, systemic chemotherapy is proposed after the effective local treatment to control symptoms; 7. Informed consent. Exclusion criteria: 1. Clinically significant hepatic dysfunction: AST or ALT &gt; 2.5 times the ULN, total serum bilirubin levels &gt; 1.5 times the ULN; clinically significant renal insufficiency: serum creatinine &gt; 1.5 times the ULN; 2. Severe heart disease: New York Heart Association class ⅢIV class of heart failure, unstable angina, myocardial infarction, coronary revascularization six months before randomization; 3. Spleen resection or combined with other severe hematopoietic system diseases; 4. Uncontrolled diabetes, hypertension (above 180/120mmHg), infection or severe gastrointestinal ulcers; 5. History or present with other cancer, except for non melanoma skin cancer, cervical cancer in situ and other cured cancer for at least 5 years; 6. Mental illness, without legal capacity or limited capacity; 7. Pregnancy, lactation or patients with pregnancy plan; 8. Participated in other clinical trail in the past 1 months or participating in other trail now; 9. Other unsuitable condition decided by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>FACT-L scale</keyword>
	<keyword>Yangzhengxiaoji</keyword>
</DOC>